Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letters to the Editor

Cancer Death and Antihypertensive Drug Treatment—Letter

Mark R. Goldstein and Luca Mascitelli
Mark R. Goldstein
1NCH Physician Group, Naples, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: markrgoldstein@comcast.net
Luca Mascitelli
2Comando Brigata Alpina “Julia”, Multinational Land Force, Medical Service, Udine, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-14-0822 Published November 2014
  • Article
  • Info & Metrics
  • PDF
Loading

The increasing cancer-related mortality related to rapid decreases in blood pressure from the pharmacologic treatment of hypertension as seen in the Systolic Hypertension in the Elderly Program (SHEP; 1) draws interesting parallels to the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial (2). The data suggest that some common treatments used for the prevention of cardiovascular disease (CVD)–related mortality in the elderly might increase cancer-related mortality in this age group, leaving all-cause mortality unchanged.

The SHEP trial randomized 4,736 elderly men and women (mean age 72 years) with isolated systolic hypertension to either placebo or chlorthalidone 12.5 mg daily and atenolol 25 mg daily if necessary to control blood pressure and reduce CVD. The active trial lasted an average of 4.5 years and subjects with remote or prevalent cancer, other than nonmelanoma skin cancer, were excluded from trial participation. Subjects alive at the end of the active trial were followed for an additional 15 years and mortality data were correlated with the intensity of active trial blood pressure reduction. Disturbingly, the degree of blood pressure reduction in the active trial correlated directly with an increase in cancer-related mortality over the 15 years. Although CVD-related mortality was decreased, all-cause mortality was unchanged.

The PROSPER trial randomized 5,804 elderly men and women (mean age 75 years) at high risk of CVD and hypercholesterolemia to either placebo or pravastatin 40 mg daily to lower blood cholesterol concentration and reduce CVD. The trial lasted an average of 3.2 years and as in the SHEP trial, a history of cancer was exclusionary for trial participation. The subjects randomized to pravastatin during the trial exhibited a reduction in CVD-related mortality; unfortunately, cancer-related mortality in the pravastatin group increased equal to the magnitude of the decrease in CVD-related mortality, leaving all-cause mortality unchanged (2).

It is plausible that the pharmacologic lowering of blood pressure and cholesterol can promote cancer in the elderly. The elderly are more likely to harbor nonclinical microscopic cancers than younger subjects. Antihypertensive treatment can stimulate de novo angiogenesis (3); and statin therapy can increase regulatory T-cell numbers and functionality (4) and inhibit natural killer cell cytotoxicity (5). Therefore, the elderly might be particularly susceptible to the promotion of nonclinical microscopic tumors from both the stimulation of angiogenesis by blood pressure lowering and immunosuppression by statin therapy. Importantly, this needs prospective investigation because hypertension and hypercholesterolemia are now more aggressively treated. Hopefully, we are not just trading mortalities.

See the Response, p. 2608

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • Received July 15, 2014.
  • Accepted July 16, 2014.
  • ©2014 American Association for Cancer Research.

References

  1. 1.↵
    1. Swerdel JN,
    2. Janevic TM,
    3. Cabrera J,
    4. Cosgrove NM,
    5. Sedjro JE,
    6. Pressel SL,
    7. et al.
    Rapid decreases in blood pressure from antihypertensive treatment were associated with increased cancer mortality in the Systolic Hypertension in the Elderly Program. Cancer Epidemiol Biomarkers Prev 2014;23:1589–97.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Shepherd J,
    2. Blauw GJ,
    3. Murphy MB,
    4. Bollen ELEM,
    5. Buckley BM,
    6. Cobbe SM,
    7. et al.
    Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–30.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Humar R,
    2. Zimmerli L,
    3. Battegay E
    . Angiogenesis and hypertension: an update. J Human Hypertension 2009;23:773–82.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Mausner-Fainberg K,
    2. Luboshits G,
    3. Mor A,
    4. Maysel-Auslender S,
    5. Rubinstein A,
    6. Karen G,
    7. et al.
    The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008;197:829–39.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Raemer PC,
    2. Kohl K,
    3. Watzl C
    . Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009;39:1456–65.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 23 (11)
November 2014
Volume 23, Issue 11
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cancer Death and Antihypertensive Drug Treatment—Letter
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cancer Death and Antihypertensive Drug Treatment—Letter
Mark R. Goldstein and Luca Mascitelli
Cancer Epidemiol Biomarkers Prev November 1 2014 (23) (11) 2607; DOI: 10.1158/1055-9965.EPI-14-0822

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cancer Death and Antihypertensive Drug Treatment—Letter
Mark R. Goldstein and Luca Mascitelli
Cancer Epidemiol Biomarkers Prev November 1 2014 (23) (11) 2607; DOI: 10.1158/1055-9965.EPI-14-0822
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk—Response
  • Copy Number Variation and Ovarian Cancer Risk—Letter
  • Shift Work, Chronotype, and Cancer Risk—Response
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement